Acute leukemia
Conditions
Interventions
interferon a-2b and decitibine group:pre-emptive therapy of interferon a-2b and decitibine
donor lymphocyte transfusions group:pre-emptive therapy of donor lymphocyte transfusions
Sponsors
the First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
12 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. with inform consent; 2. Aged 12-60 years; 3. At least one of the following conditions with relapse tendency were met: (1) 3–5% bone marrow blasts; (2) MRD >=1*10^3; (3) Positive specific fusion gene detection or WT-1 gene copy number > 200 copies/10,000 abl copies; (4) DC <=90% detected by short tandem repeat (STR) technology; 4.No contraindication for pre-emptive therapy: active infection, liver and renal function damage.
Exclusion criteria
Exclusion criteria: 1. uncontrolled infection or significant bleeding; 2. Organ failure; 3. over grade III graft-versus-host disease (GVHD) of patients with relapse tendency; 4. hematologic relapse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival;Overall Survival;Disease Response;accumulated disease progressed or inefficiency rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-hematologic toxicity;hematologic toxicity;graft-versus-host disease; | — |
Countries
China
Contacts
Public ContactWu Depei?Tang XiaoWen
Outcome results
None listed